World's Best Scientists 2026 revealed!
Michael A. Nauck

Michael A. Nauck

D-Index & Metrics

Medicine

D-Index
119
Citations
82753
World Ranking
3808
National Ranking
208

Overview

Michael A. Nauck is affiliated with Ruhr University Bochum in Germany and has a primary research focus within the field of medicine, particularly endocrinology, diabetes, and metabolism. Their work spans various subfields including molecular biology, surgery, physiology, and pharmacology.

The scientist has contributed extensively to topics linked to diabetes treatment and management, diabetes research, metabolism, cancer related to diabetes, diet and metabolism studies, pancreatic function, pharmacology, obesity treatment, as well as diabetes-associated disorders.

Frequent co-authors in their research include:

  • Juris J. Meier
  • Daniel R. Quast
  • John B. Buse
  • Andreas L. Birkenfeld
  • Monika Kellerer

Their publications often appear in several specialized scientific and medical journals. The most frequent publication venues are:

  • Diabetologie und Stoffwechsel
  • Diabetes Obesity and Metabolism
  • Diabetes Care
  • Cardiovascular Diabetology
  • Experimental and Clinical Endocrinology & Diabetes

Recent papers authored by Michael A. Nauck demonstrate a consistent engagement with topics relevant to diabetes and metabolism. These include:

  • GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art (2020, Molecular Metabolism)
  • The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update (2021, Diabetes Obesity and Metabolism)
  • Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction (2022, Cardiovascular Diabetology)

Other related impactful publications from the same period, though not authored by them but relevant to their field, include studies on COVID-19 and diabetes mellitus, and consensus definitions in diabetes remission.

Best Publications

  • Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

    Steven P. Marso;Gilbert H. Daniels;Kirstine Brown-Frandsen;Peter Kristensen

  • The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

    Daniel J Drucker;Michael A Nauck

  • Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

    Silvio E. Inzucchi;Richard M. Bergenstal;John B. Buse;Michaela Diamant

  • Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

    Silvio E Inzucchi;Richard M Bergenstal;John B Buse;Michaela Diamant

  • Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

    Silvio E. Inzucchi;Richard M. Bergenstal;John B. Buse;Michaela Diamant

  • Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

    M A Nauck;M M Heimesaat;C Orskov;J J Holst

  • Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.

    M. Nauck;F. Stöckmann;R. Ebert;W. Creutzfeldt

  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    Adrian F Hernandez;Jennifer B Green;Salim Janmohamed;Ralph B D'Agostino

  • Glucagon-like peptide 1 (GLP-1)

    T.D. Müller;B. Finan;S.R. Bloom;D. D'Alessio

  • Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

    Michael Nauck;Anders Frid;Kjeld Hermansen;Nalini S. Shah

  • Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36)amide in type 2 (non-insulin-dependent) diabetic patients

    M. A. Nauck;N. Kleine;C. Orskov;J. J. Holst

  • Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

    Michael A. Nauck;Ulrich Niedereichholz;Rainer Ettler;Jens Juul Holst

  • Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

    M A Nauck;E Homberger;E G Siegel;R C Allen

  • Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

    Carolyn F Deacon;Michael A Nauck;Maibritt Toft-Nielsen;Lone Pridal

  • GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

    Michael A. Nauck;Daniel R. Quast;Jakob Wefers;Juris J. Meier

  • COVID-19 and diabetes mellitus: from pathophysiology to clinical management.

    Soo Lim;Jae Hyun Bae;Hyuk Sang Kwon;Michael A. Nauck

  • Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

    Michael A. Nauck;Markus M. Heimesaat;Kai Behle;Jens J. Holst

  • Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

    Silvio E. Inzucchi;Richard M. Bergenstal;John B. Buse;Michaela Diamant

  • Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

    B Willms;J Werner;J J Holst;C Orskov

  • Erratum: Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Diabetologia (2013) 56 (680))

    S. E. Inzucchi;R. M. Bergenstal;John B Buse;M. Diamant

Frequent Co-Authors

Juris J. Meier
Juris J. Meier Ruhr University Bochum
Jens J. Holst
Jens J. Holst University of Copenhagen
John B. Buse
John B. Buse University of North Carolina at Chapel Hill
Werner Creutzfeldt
Werner Creutzfeldt University of Göttingen
David R. Matthews
David R. Matthews University of Oxford
Wolff Schmiegel
Wolff Schmiegel Ruhr University Bochum
Carolyn F. Deacon
Carolyn F. Deacon University of Copenhagen
Johannes F.E. Mann
Johannes F.E. Mann University of Erlangen-Nuremberg
Michael Horowitz
Michael Horowitz University of Adelaide
Neil R. Poulter
Neil R. Poulter Imperial College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in the medical field, there are diverse online degree options that can complement or serve as alternative pathways to studying Medicine in the USA. Many students kickstart their healthcare careers by pursuing nursing. If cost is a concern, you can explore the cheapest rn to bsn online programs, which allow registered nurses to advance their qualifications affordably and flexibly from home.

For individuals holding a non-nursing bachelor's degree, specialized direct entry online msn programs provide a fast track into advanced nursing roles—often without needing prior nursing experience. Some prospective students are concerned about admissions competitiveness, but there are easiest nursing schools to get into that can offer more accessible entry points into nursing education.

For those seeking non-clinical yet vital healthcare roles, becoming a medical coder or biller is worth considering. There are reputable online medical billing and coding schools that accept fafsa, making this career path possible with financial aid support.

Best Scientists Citing Michael A. Nauck

Trending Scientists